8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 4, 2026·SEC
Viatris Inc.(VTRS)Earnings, Financials & Key Ratios
VTRS•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryLarge-scale generic drug manufacturers
AboutViatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.Show more
- Revenue$14.3B-3.0%
- EBITDA$135M-95.3%
- Net Income-$3.51B-454.2%
- EPS (Diluted)-3.00-466.0%
- Gross Margin35.06%-8.1%
- EBITDA Margin0.95%-95.2%
- Operating Margin-18.62%-27287.2%
- Net Margin-24.58%-471.3%
- ROE-21.08%-549.9%
VTRS Key Insights
Viatris Inc. (VTRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Healthy dividend yield of 3.1%
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Profits declining 39.3% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VTRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VTRS Price & Volume
Viatris Inc. (VTRS) stock price & volume — 10-year historical chart
Loading chart...
VTRS Growth Metrics
Viatris Inc. (VTRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.25%
5 Years3.66%
3 Years-4.2%
TTM1.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM92.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.68%
Return on Capital
10 Years1.04%
5 Years-0.53%
3 Years-2.07%
Last Year-8.09%
VTRS Recent Earnings
Viatris Inc. (VTRS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.59+17.5%
$0.50
Rev
$3.5B+4.8%
$3.4B
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.57+7.1%
$0.53
Rev
$3.7B+4.8%
$3.5B
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.67+7.9%
$0.62
Rev
$3.8B+3.8%
$3.6B
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.62+11.5%
$0.56
Rev
$3.6B+3.3%
$3.5B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.59vs $0.50+17.5% | $3.5Bvs $3.4B+4.8% |
| Q1 2026 | Feb 26, 2026 | $0.57vs $0.53+7.1% | $3.7Bvs $3.5B+4.8% |
| Q4 2025 | Nov 6, 2025 | $0.67vs $0.62+7.9% | $3.8Bvs $3.6B+3.8% |
| Q3 2025 | Aug 7, 2025 | $0.62vs $0.56+11.5% | $3.6Bvs $3.5B+3.3% |
Based on last 12 quarters of dataView full earnings history →
VTRS Peer Comparison
Viatris Inc. (VTRS) competitors in Large-scale generic drug manufacturers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TEVA | 36.66B | 31.48 | 26.23 | 4.31% | 9.02% | 20.69% | 2.20 | |
 AMRX | 5.1B | 16.21 | 73.68 | 8.05% | 2.39% | 7.47% | 0.13 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 LPTX | 64.53M | 0.77 | 10.99 | -272.29% | -46.86% | 0.00 | ||
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% |
Compare VTRS vs Peers
Viatris Inc. (VTRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VTRS Income Statement
Viatris Inc. (VTRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 11.91B | 11.43B | 11.5B | 11.95B | 17.89B | 16.26B | 15.43B | 14.74B | 14.3B | 14.56B |
Revenue Growth % | 7.5% | -3.98% | 0.58% | 3.87% | 49.73% | -9.08% | -5.14% | -4.46% | -2.98% | 1.62% |
Cost of Goods Sold | 7.12B | 7.43B | 7.6B | 8.15B | 12.31B | 9.77B | 8.99B | 9.12B | 9.29B | 9.55B |
COGS % of Revenue | 59.83% | 65% | 66.11% | 68.22% | 68.83% | 60.05% | 58.26% | 61.85% | 64.94% | - |
Gross Profit | 4.78B▲ 0% | 4B▼ 16.3% | 3.9B▼ 2.6% | 3.8B▼ 2.6% | 5.58B▲ 46.9% | 6.5B▲ 16.5% | 6.44B▼ 0.9% | 5.62B▼ 12.7% | 5.01B▼ 10.8% | 5.01B▲ 0% |
Gross Margin % | 40.17% | 35% | 33.89% | 31.78% | 31.17% | 39.95% | 41.74% | 38.15% | 35.06% | 34.4% |
Gross Profit Growth % | 1.83% | -16.34% | -2.6% | -2.59% | 46.85% | 16.53% | -0.9% | -12.66% | -10.85% | - |
Operating Expenses | 3.35B | 3.1B | 3.18B | 4.01B | 5.61B | 4.88B | 5.67B | 5.61B | 7.68B | 4.87B |
OpEx % of Revenue | 28.1% | 27.08% | 27.67% | 33.55% | 31.36% | 30.02% | 36.77% | 38.09% | 53.68% | - |
Selling, General & Admin | 2.58B | 2.44B | 2.56B | 3.34B | 4.53B | 4.18B | 4.65B | 4.43B | 3.79B | 3.77B |
SG&A % of Revenue | 21.63% | 21.35% | 22.29% | 28% | 25.32% | 25.7% | 30.14% | 30.03% | 26.53% | - |
Research & Development | 783.3M | 704.5M | 639.9M | 512.6M | 681M | 662.2M | 805.2M | 808.7M | 965.9M | 992.5M |
R&D % of Revenue | 6.58% | 6.16% | 5.56% | 4.29% | 3.81% | 4.07% | 5.22% | 5.49% | 6.75% | - |
Other Operating Expenses | -13.1M | -49.5M | -21.4M | 150.3M | 399.3M | 40.8M | 217.1M | 379.2M | 2.92B | 1000K |
Operating Income | 1.44B▲ 0% | 905.6M▼ 37.0% | 715.5M▼ 21.0% | -210.8M▼ 129.5% | -34M▲ 83.9% | 1.61B▲ 4849.7% | 766.2M▼ 52.6% | 10.1M▼ 98.7% | -2.66B▼ 26467.3% | 139.4M▲ 0% |
Operating Margin % | 12.07% | 7.92% | 6.22% | -1.76% | -0.19% | 9.93% | 4.97% | 0.07% | -18.62% | 0.96% |
Operating Income Growth % | 105.55% | -36.99% | -20.99% | -129.46% | 83.87% | 4849.71% | -52.55% | -98.68% | -26467.33% | - |
EBITDA | 3.24B | 3.02B | 2.73B | 2.01B | 4.47B | 4.64B | 3.51B | 2.9B | 135.2M | 2.32B |
EBITDA Margin % | 27.23% | 26.37% | 23.78% | 16.79% | 25.01% | 28.55% | 22.73% | 19.7% | 0.95% | 15.93% |
EBITDA Growth % | 45.94% | -7.02% | -9.31% | -26.67% | 123.03% | 3.8% | -24.47% | -17.21% | -95.34% | 1209.76% |
D&A (Non-Cash Add-back) | 1.81B | 2.11B | 2.02B | 2.22B | 4.51B | 3.03B | 2.74B | 2.89B | 2.8B | 2.13B |
EBIT | 1.44B | 840.7M | 671.7M | -223.4M | -28.2M | 3.41B | 776M | -73.2M | -3.19B | -244.4M |
Net Interest Income | -534.6M | -542.3M | -517.3M | -497.8M | -636.2M | -592.4M | -573.1M | -550M | -471.3M | -475.9M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 534.6M | 542.3M | 517.3M | 497.8M | 636.2M | 592.4M | 573.1M | 550M | 471.3M | 475.9M |
Other Income/Expense | -534.2M | -607.2M | -561.1M | -510.4M | -630.4M | 1.2B | -563.3M | -633.3M | -1B | -954.7M |
Pretax Income | 903M▲ 0% | 298.4M▼ 67.0% | 154.4M▼ 48.3% | -721.2M▼ 567.1% | -664.4M▲ 7.9% | 2.81B▲ 523.4% | 202.9M▼ 92.8% | -623.2M▼ 407.1% | -3.67B▼ 488.1% | -815.3M▲ 0% |
Pretax Margin % | 7.58% | 2.61% | 1.34% | -6.04% | -3.71% | 17.3% | 1.32% | -4.23% | -25.63% | -5.6% |
Income Tax | 207M | -54.1M | 137.6M | -51.3M | 604.7M | 734.6M | 148.2M | 11M | -150.1M | -518.8M |
Effective Tax Rate % | 22.92% | -18.13% | 89.12% | 7.11% | -91.01% | 26.11% | 73.04% | -1.77% | 4.1% | 63.63% |
Net Income | 696M▲ 0% | 352.5M▼ 49.4% | 16.8M▼ 95.2% | -669.9M▼ 4087.5% | -1.27B▼ 89.4% | 2.08B▲ 263.8% | 54.7M▼ 97.4% | -634.2M▼ 1259.4% | -3.51B▼ 454.2% | -296.5M▲ 0% |
Net Margin % | 5.85% | 3.08% | 0.15% | -5.61% | -7.1% | 12.78% | 0.35% | -4.3% | -24.58% | -2.04% |
Net Income Growth % | 45% | -49.35% | -95.23% | -4087.5% | -89.45% | 263.79% | -97.37% | -1259.42% | -454.23% | 92.18% |
Net Income (Continuing) | 696M | 352.5M | 16.8M | -669.9M | -1.27B | 2.08B | 54.7M | -634.2M | -3.51B | -296.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.30▲ 0% | 0.68▼ 47.7% | 0.03▼ 95.6% | -1.11▼ 3800.0% | -1.05▲ 5.4% | 1.71▲ 262.9% | 0.05▼ 97.4% | -0.53▼ 1270.0% | -3.00▼ 466.0% | -0.25▲ 0% |
EPS Growth % | 41.3% | -47.69% | -95.59% | -3800% | 5.41% | 262.86% | -97.35% | -1269.98% | -466.04% | 91.68% |
EPS (Basic) | 1.30 | 0.69 | 0.03 | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 | - |
Diluted Shares Outstanding | 536.7M | 516.5M | 516.5M | 601.2M | 1.21B | 1.22B | 1.21B | 1.19B | 1.17B | 1.18B |
Basic Shares Outstanding | 535.38M | 516.5M | 560M | 601.2M | 1.21B | 1.21B | 1.2B | 1.19B | 1.17B | 1.16B |
Dividend Payout Ratio | - | - | - | - | - | 27.98% | 1052.29% | - | - | - |
VTRS Balance Sheet
Viatris Inc. (VTRS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.21B | 6.37B | 6.76B | 12.87B | 10.9B | 10.64B | 12.98B | 9.52B | 9.22B | 10.92B |
Cash & Short-Term Investments | 418.9M | 449.2M | 584.7M | 1.05B | 935M | 1.47B | 1.18B | 1.09B | 1.45B | 1.8B |
Cash Only | 292.1M | 388.1M | 475.6M | 844.4M | 701.2M | 1.26B | 991.9M | 734.8M | 1.35B | 1.8B |
Short-Term Investments | 110.6M | 57.5M | 109.1M | 203.5M | 233.8M | 212.6M | 192.5M | 355.1M | 106.4M | 0 |
Accounts Receivable | 3.17B | 2.42B | 3.06B | 4.84B | 4.27B | 4.14B | 4.04B | 3.52B | 3.35B | 3.08B |
Days Sales Outstanding | 97.26 | 77.14 | 97.08 | 148 | 87.06 | 92.98 | 95.6 | 87.22 | 85.43 | 85.27 |
Inventory | 2.54B | 2.58B | 2.67B | 5.47B | 3.98B | 3.52B | 3.47B | 3.85B | 4B | 3.93B |
Days Inventory Outstanding | 130.26 | 126.71 | 128.22 | 245.08 | 117.93 | 131.54 | 140.9 | 154.32 | 157.19 | 155.71 |
Other Current Assets | 958.8M | 791.2M | 286.2M | 1.24B | 1.47B | 1.31B | 4.13B | 913.8M | 194.8M | 2.11B |
Total Non-Current Assets | 28.59B | 26.37B | 24.5B | 48.69B | 43.94B | 39.39B | 34.71B | 31.98B | 27.97B | 25.92B |
Property, Plant & Equipment | 2.34B | 2.17B | 2.4B | 3.78B | 3.48B | 3.28B | 3.01B | 2.92B | 2.89B | 2.53B |
Fixed Asset Turnover | 5.09x | 5.27x | 4.78x | 3.16x | 5.14x | 4.95x | 5.13x | 5.05x | 4.96x | 5.19x |
Goodwill | 10.21B | 9.75B | 9.59B | 12.35B | 12.11B | 10.43B | 9.87B | 9.13B | 6.75B | 6.69B |
Intangible Assets | 15.25B | 13.66B | 11.65B | 29.68B | 26.13B | 22.61B | 19.18B | 17.07B | 15.1B | 14.48B |
Long-Term Investments | 226M | 138.7M | 92.2M | 47.9M | 81.4M | 1.09B | 1.14B | 1.35B | 815M | 2.62B |
Other Non-Current Assets | 79.6M | 73.7M | 58.2M | 676M | 798.5M | 1.05B | 821.1M | 754M | 1.35B | 1.11B |
Total Assets | 35.81B▲ 0% | 32.73B▼ 8.6% | 31.26B▼ 4.5% | 61.55B▲ 96.9% | 54.84B▼ 10.9% | 50.02B▼ 8.8% | 47.69B▼ 4.7% | 41.5B▼ 13.0% | 37.19B▼ 10.4% | 36.83B▲ 0% |
Asset Turnover | 0.33x | 0.35x | 0.37x | 0.19x | 0.33x | 0.33x | 0.32x | 0.36x | 0.38x | 0.39x |
Asset Growth % | 3.11% | -8.58% | -4.52% | 96.93% | -10.9% | -8.79% | -4.67% | -12.97% | -10.38% | -45.18% |
Total Current Liabilities | 6.39B | 4.59B | 5.57B | 10.56B | 9.88B | 6.75B | 7.78B | 5.78B | 7.09B | 6.81B |
Accounts Payable | 1.45B | 1.24B | 1.06B | 1.35B | 1.06B | 1.16B | 1.38B | 1.36B | 1.29B | 1.75B |
Days Payables Outstanding | 74.41 | 61.13 | 50.98 | 60.27 | 31.31 | 43.28 | 56.1 | 54.27 | 50.85 | 54.35 |
Short-Term Debt | 1.8B | 657.1M | 1.46B | 3.41B | 3.35B | 1.25B | 1.93B | 600K | 2.04B | 1.93B |
Deferred Revenue (Current) | 1.51B | 1.22B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.62B | 2.29B | 832.8M | 2.22B | 1.41B | 1.24B | 1.41B | 1.34B | 2.88B | 3.13B |
Current Ratio | 1.13x | 1.39x | 1.21x | 1.22x | 1.10x | 1.58x | 1.67x | 1.65x | 1.30x | 1.60x |
Quick Ratio | 0.73x | 0.83x | 0.73x | 0.70x | 0.70x | 1.05x | 1.22x | 0.98x | 0.74x | 1.03x |
Cash Conversion Cycle | 153.12 | 142.73 | 174.32 | 332.81 | 173.68 | 181.25 | 180.4 | 187.27 | 191.77 | 186.64 |
Total Non-Current Liabilities | 16.11B | 15.98B | 13.8B | 28.04B | 24.47B | 22.2B | 19.44B | 17.09B | 15.39B | 15.37B |
Long-Term Debt | 12.87B | 13.16B | 11.21B | 22.43B | 19.72B | 18.02B | 16.19B | 14.04B | 12.48B | 12.41B |
Capital Lease Obligations | 0 | 0 | 175.7M | 229.5M | 200.9M | 181.4M | 165.4M | 179.3M | 178.1M | 531.5M |
Deferred Tax Liabilities | 2.01B | 1.72B | 1.63B | 3.12B | 2.81B | 2.43B | 1.74B | 1.11B | 892M | 3.87B |
Other Non-Current Liabilities | 1.24B | 1.1B | 785.1M | 2.25B | 1.73B | 1.58B | 1.35B | 1.76B | 1.84B | 2.08B |
Total Liabilities | 22.5B | 20.57B | 19.37B | 38.6B | 34.35B | 28.95B | 27.22B | 22.87B | 22.48B | 22.18B |
Total Debt | 14.66B | 13.82B | 12.92B | 26.16B | 23.36B | 19.53B | 18.37B | 14.31B | 14.7B | 14.34B |
Net Debt | 14.37B | 13.43B | 12.45B | 25.32B | 22.66B | 18.27B | 17.38B | 13.57B | 13.35B | 12.54B |
Debt / Equity | 1.10x | 1.14x | 1.09x | 1.14x | 1.14x | 0.93x | 0.90x | 0.77x | 1.00x | 0.98x |
Debt / EBITDA | 4.52x | 4.58x | 4.73x | 13.05x | 5.22x | 4.21x | 5.24x | 4.93x | 108.74x | 6.18x |
Net Debt / EBITDA | 4.43x | 4.45x | 4.55x | 12.62x | 5.07x | 3.93x | 4.96x | 4.67x | 98.77x | 5.40x |
Interest Coverage | 2.69x | 1.55x | 1.30x | -0.45x | -0.04x | 5.75x | 1.35x | -0.13x | -6.78x | -0.51x |
Total Equity | 13.31B▲ 0% | 12.17B▼ 8.6% | 11.88B▼ 2.3% | 22.95B▲ 93.2% | 20.49B▼ 10.7% | 21.07B▲ 2.8% | 20.47B▼ 2.9% | 18.64B▼ 9.0% | 14.71B▼ 21.1% | 14.66B▲ 0% |
Equity Growth % | 19.7% | -8.57% | -2.33% | 93.15% | -10.72% | 2.83% | -2.87% | -8.95% | -21.06% | -70.75% |
Book Value per Share | 24.80 | 23.56 | 23.01 | 38.18 | 16.95 | 17.31 | 16.96 | 15.62 | 12.57 | 12.47 |
Total Shareholders' Equity | 13.31B | 12.17B | 11.88B | 22.95B | 20.49B | 21.07B | 20.47B | 18.64B | 14.71B | 14.66B |
Common Stock | 6M | 6M | 6.1M | 12.1M | 12.1M | 12.1M | 12.2M | 12.3M | 12.5M | 12.6M |
Retained Earnings | 5.64B | 6.01B | 6.03B | 5.36B | 3.69B | 5.18B | 4.64B | 3.42B | -388.3M | -211.9M |
Treasury Stock | -567.7M | -999.7M | -999.7M | 0 | 0 | 0 | -251.8M | -504.3M | -1.01B | -1.01B |
Accumulated OCI | -361.2M | -1.44B | -1.8B | -858M | -1.74B | -2.76B | -2.75B | -3.21B | -2.71B | -2.8B |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VTRS Cash Flow Statement
Viatris Inc. (VTRS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 2.06B | 2.34B | 1.8B | 1.23B | 3.02B | 3B | 2.8B | 2.3B | 2.32B | 2.17B |
Operating CF Margin % | 17.34% | 20.48% | 15.68% | 10.31% | 16.87% | 18.44% | 18.15% | 15.62% | 16.2% | - |
Operating CF Growth % | 0.86% | 13.41% | -22.97% | -31.71% | 144.92% | -0.59% | -6.65% | -17.74% | 0.56% | -10.4% |
Net Income | 696M | 352.5M | 16.8M | -669.9M | -1.27B | 2.08B | 54.7M | -634.2M | -3.51B | -296.5M |
Depreciation & Amortization | 1.73B | 1.89B | 2.02B | 2.22B | 4.51B | 3.03B | 2.74B | 2.71B | 2.8B | 2.81B |
Stock-Based Compensation | 74.7M | -70.6M | 56.8M | 79.2M | 111.2M | 116.4M | 180.7M | 146.1M | 177.7M | 122.5M |
Deferred Taxes | -111.4M | -264.3M | -192.6M | -213.2M | 675.7M | -25.9M | -387.1M | -767.6M | -476.5M | -502.6M |
Other Non-Cash Items | 277.9M | 556.6M | 411.2M | 515.9M | 797.4M | -1.28B | 922.1M | 1.17B | 5.84B | 3.02B |
Working Capital Changes | -712M | -385.4M | -507.8M | -696.3M | -1.8B | -922.6M | -711.3M | -318.6M | -2.5B | -2.99B |
Change in Receivables | -162.2M | 340.1M | -20M | 78.7M | 59.3M | -240.3M | 78.6M | 300.1M | 334.6M | 40.3M |
Change in Inventory | -129.5M | -547.6M | -512.9M | -741.9M | -427.6M | -259.5M | -613.3M | -723.4M | -106.4M | -35.7M |
Change in Payables | 14.4M | 220.3M | -96.3M | -82.7M | -70.4M | 170.2M | 314.7M | 36M | -168M | -236.9M |
Cash from Investing | -976.4M | -1.21B | -525.4M | -301.1M | -117.8M | 1.47B | -764.1M | 1.8B | -427.7M | -85.2M |
Capital Expenditures | -275.9M | -252.1M | -406M | -681.2M | -509.4M | -489.4M | -377M | -326M | -378.8M | -541M |
CapEx % of Revenue | 2.32% | 2.2% | 3.53% | 5.7% | 2.85% | 3.01% | 2.44% | 2.21% | 2.65% | 3.71% |
Acquisitions | -167M | -65.9M | -148.7M | 415.8M | 277M | 0 | -667.7M | -350M | 0 | 1.6M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -533.5M | -892.4M | 28M | 22.1M | 115M | 1.96B | 280.6M | 2.48B | -48.9M | 54.2M |
Cash from Financing | -1.89B | -1.09B | -1.17B | -605.7M | -3.01B | -3.88B | -2.3B | -4.33B | -1.29B | -1.03B |
Debt Issued (Net) | -1.36B | -631.7M | -1.1B | -401.3M | -2.1B | -3.28B | -1.25B | -3.71B | 0 | 300K |
Equity Issued (Net) | -500.2M | -432M | 0 | 600K | -17.4M | 3.3M | -246.9M | -247.5M | -497.9M | -322.6M |
Dividends Paid | 0 | 0 | 0 | 0 | -399M | -581.6M | -575.6M | -574.8M | -561.2M | -557.5M |
Share Repurchases | -500.2M | -432M | 0 | 0 | -17.4M | 0 | -250M | -250M | -500.5M | -325.1M |
Other Financing | -33.4M | -27.2M | -66.1M | -205M | -496.5M | -19.5M | -229.8M | 205.6M | -234.8M | -150.9M |
Net Change in Cash | -777.1M▲ 0% | 19.4M▲ 102.5% | 101.8M▲ 424.7% | 358.9M▲ 252.6% | -143.8M▼ 140.1% | 556.3M▲ 486.9% | -268.9M▼ 148.3% | -257.5M▲ 4.2% | 611.9M▲ 337.6% | 1.05B▲ 0% |
Free Cash Flow | 1.79B▲ 0% | 2.09B▲ 16.8% | 1.4B▼ 33.1% | 550.6M▼ 60.6% | 2.51B▲ 355.4% | 2.51B▲ 0.1% | 2.33B▼ 7.4% | 1.98B▼ 15.0% | 1.94B▼ 2.0% | 1.71B▲ 0% |
FCF Margin % | 15.02% | 18.28% | 12.15% | 4.61% | 14.02% | 15.43% | 15.07% | 13.41% | 13.55% | 11.74% |
FCF Growth % | 7.97% | 16.81% | -33.11% | -60.61% | 355.41% | 0.08% | -7.35% | -14.98% | -2.01% | -7.57% |
FCF per Share | 3.33 | 4.05 | 2.71 | 0.92 | 2.07 | 2.06 | 1.93 | 1.66 | 1.65 | 1.45 |
FCF Conversion (FCF/Net Income) | 2.97x | 6.64x | 107.36x | -1.84x | -2.38x | 1.44x | 51.18x | -3.63x | -0.66x | -5.77x |
Interest Paid | 474M | 460.8M | 470.6M | 555.4M | 684.8M | 642.5M | 611.6M | 561.1M | 0 | 0 |
Taxes Paid | 285.7M | 228.6M | 278.6M | 324.4M | 641.7M | 735.2M | 570.9M | 514M | 0 | 0 |
VTRS Key Ratios
Viatris Inc. (VTRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 5.7% | 2.77% | 0.14% | -3.85% | -5.84% | 10% | 0.26% | -3.24% | -21.08% | -1.97% |
Return on Invested Capital (ROIC) | 4.05% | 2.55% | 2.15% | -0.44% | -0.06% | 2.94% | 1.49% | 0.02% | -6.63% | 0.37% |
Gross Margin | 40.17% | 35% | 33.89% | 31.78% | 31.17% | 39.95% | 41.74% | 38.15% | 35.06% | 34.4% |
Net Margin | 5.85% | 3.08% | 0.15% | -5.61% | -7.1% | 12.78% | 0.35% | -4.3% | -24.58% | -2.04% |
Debt / Equity | 1.10x | 1.14x | 1.09x | 1.14x | 1.14x | 0.93x | 0.90x | 0.77x | 1.00x | 0.98x |
Interest Coverage | 2.69x | 1.55x | 1.30x | -0.45x | -0.04x | 5.75x | 1.35x | -0.13x | -6.78x | -0.51x |
FCF Conversion | 2.97x | 6.64x | 107.36x | -1.84x | -2.38x | 1.44x | 51.18x | -3.63x | -0.66x | -5.77x |
Revenue Growth | 7.5% | -3.98% | 0.58% | 3.87% | 49.73% | -9.08% | -5.14% | -4.46% | -2.98% | 1.62% |
Related:VTRS Dividend History·VTRS Revenue History·VTRS Price History·VTRS P/E History·VTRS Financial Ratios·VTRS Institutional Holders
VTRS SEC Filings & Documents
Viatris Inc. (VTRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
VTRS Frequently Asked Questions
Viatris Inc. (VTRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Viatris Inc. (VTRS) reported $14.56B in revenue for fiscal year 2025. This represents a 959% increase from $1.37B in 2003.
Viatris Inc. (VTRS) saw revenue decline by 3.0% over the past year.
Viatris Inc. (VTRS) reported a net loss of $296.5M for fiscal year 2025.
Dividend & Returns
Yes, Viatris Inc. (VTRS) pays a dividend with a yield of 3.12%. This makes it attractive for income-focused investors.
Viatris Inc. (VTRS) has a return on equity (ROE) of -21.1%. Negative ROE indicates the company is unprofitable.
Viatris Inc. (VTRS) generated $1.71B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.